Thomas Gad Sells 7,351 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Free Report) insider Thomas Gad sold 7,351 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the transaction, the insider now owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Thomas Gad also recently made the following trade(s):

  • On Tuesday, May 21st, Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $300,000.00.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB traded down $0.45 during mid-day trading on Thursday, hitting $12.40. The company had a trading volume of 246,556 shares, compared to its average volume of 403,128. The firm has a fifty day moving average price of $14.66 and a 200 day moving average price of $11.63. The company has a market capitalization of $544.11 million, a PE ratio of -25.31 and a beta of 0.78. Y-mAbs Therapeutics, Inc. has a one year low of $4.60 and a one year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.17. The company had revenue of $23.36 million during the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. Research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

YMAB has been the subject of several analyst reports. BMO Capital Markets raised their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a report on Monday, March 4th. HC Wainwright raised their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Canaccord Genuity Group raised their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, Wedbush reiterated an “outperform” rating and issued a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of “Hold” and a consensus price target of $17.33.

Read Our Latest Stock Analysis on YMAB

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $34,000. Tower Research Capital LLC TRC increased its stake in Y-mAbs Therapeutics by 345.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock valued at $46,000 after purchasing an additional 5,185 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares in the last quarter. Bailard Inc. bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $115,000. Finally, SG Americas Securities LLC increased its stake in Y-mAbs Therapeutics by 17.5% during the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after purchasing an additional 3,210 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

See Also

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.